Loading
A phase 1/2 trial of an investigational treatment in acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, myelodysplastic syndromes / neoplasms and hodgkin lymphoma, run by Ossium Health, Inc., active and no longer recruiting.
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies is a phase 1/2 interventional study registered as NCT05589896 by Ossium Health, Inc., with 12 participants enrolled, started 2024-08-16 and due to reach its primary completion in 2026-07-14.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Chronic myeloid leukaemia (CML), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.